10IU Jintropin Somatropin HGH Peptide Hormones For Big Muscle

Full 10IU Jintropin Somatropin HGH Protein Peptide Hormones for Big Muscle

What is Jintropin HGH?

Jintropin made by GeneScience is the most popular rHGH sold in China. According to IMS, an internationally recognized marketing firm, jintropin is the absolute market leader in China with just over 75% market share.

GenSci uses a proprietary technology called E.coli secretion technology which will produce a 191 amino acid sequence human growth hormone. This produces a high quality highly purified product resulting in no side effects associated with injection, such as red rash or welts at the injection site. This technology also has the advantage that growth hormone produced using secretion technology is very stable; it can be stable at 37C or 98F degrees for about 30 days. When refrigerated it can be stable for a year.

Jintropin is now the most well known and respected brand of rhGH in China and sought after around the world

whatsapp:+8613429837396

Benefits of HGH

As Jintropin Human Growth Hormone (HGH) can provide benefit in many areas, we have divided the main therapeutic indcations into categories and provided links to medical resources where you can learn more.

The biopharmaceuticals field is progressing very quickly, and new products such as JINTROPIN are making a big difference to those who want the benefits of a trustworthy product, but who don't want to pay for the brand name on the box when there is no perceivable difference in quality. Established brands charge much higher prices because they used to have a monopoly in the HGH market, but our clients can now benefit from the efforts of smaller companies who are creating excellent products at much more competitive prices.

We firmly believe that the best way for you to decide whether JINTROPIN is right for you is to read these independent third party resources for yourself and come to your own conclusions. The clinical research speaks for itself!

What is Jintropin? 

Jintropin therapy should be used only under the supervision of a qualified physician experienced in the management of patients with growth hormone deficiency.

The dosage of administration of Jintropin should be individualised for each patient.

The duration of treatment, usually a period of several years will depend on maximum achievable therapeutic benefit.

The subcutaneous administration of growth hormone may lead to loss or increase of adipose tissue at the injection site. Therefore, injection sites should be alternated.

The injection should be given subcutaneously and the site varied to prevent lipoatrophy.

Exclusion Criteria:

• Participants with abnormal liver and kidney functions (ALT > upper limit 1.5 times of normal value; Cr > upper limit of normal value);
• Participants are positive for anti-HBc, HbsAg or HbeAg in Hepatitis B virus tests;
• Participants with known highly allergic constitution or allergy to investigational product or its excipient;
• Participants with systemic chronic disease and immune deficiency;
• Participants diagnosed with tumor, or with potential high tumor risks such as tumor markers exceed normal range and some other relative information may be excluded from the treatment;
• Participants with mental disease;
• Participants with other types of abnormal growth and development;
  1. Growth hormone deficiency (GHD) (confirmed by GH stimulation test);
  2. Turner syndrome (confirmed by karyotype test of girls);
  3. Noonan syndrome (hypertelorism, pectus carinatum, hypophrenia, frequently with skin disease and congenital heart disease, missense mutation of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene on chromosome 12 for half of the participants, for both male and female participants);
  4. Laron syndrome (confirmed by IGF-1 generation test);
  5. Small for gestational age ( the birth height or weight is below the tenth percentile or 2 SD, with catch-up growth uncompleted at 2 years old);
  6. Growth disorders caused by malnutrition or hypothyroidism (thyroid function test).
• Participants with impaired glucose regulation (IGR) (including impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) ) or diabetes;
• BMI (Body mass index) ≥22kg/m²;
• Congenital skeletal abnormalities or scoliosis, claudication;
• Participants who took part in other clinical trials within 3 months;
• Participants who received medications which may interfere GH secretion or GH function, or other hormones within 3 months (such as sex steroids, glucocorticoids, etc.);
• Other conditions which is inappropriate for this study in the opinion of the investigator.

Other Products List: